These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cost analysis of post-polio certification immunization policies. Sangrujee N; Cáceres VM; Cochi SL Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295 [TBL] [Abstract][Full Text] [Related]
5. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Dempsey AF; Zimet GD; Davis RL; Koutsky L Pediatrics; 2006 May; 117(5):1486-93. PubMed ID: 16651301 [TBL] [Abstract][Full Text] [Related]
6. Parental attitudes toward multiple poliovirus injections following a provider recommendation. Kolasa MS; Bisgard KM; Prevots DR; Desai SN; Dibling K Public Health Rep; 2001; 116(4):282-8. PubMed ID: 12037256 [TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of alternative polio immunization policies in South Africa. Griffiths UK; Botham L; Schoub BD Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096 [TBL] [Abstract][Full Text] [Related]
12. A developing country perspective on vaccine-associated paralytic poliomyelitis. John TJ Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301 [TBL] [Abstract][Full Text] [Related]
13. [Worldwide eradication of poliomyelitis]. Rasch G; Schreier E; Kiehl W; Kurth R Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120 [TBL] [Abstract][Full Text] [Related]
14. Inactivated polio vaccine: time to introduce it in India's national immunization schedule. Verma R; Khanna P; Chawla S Hum Vaccin Immunother; 2012 Jul; 8(7):956-8. PubMed ID: 22699444 [TBL] [Abstract][Full Text] [Related]
15. Anomalous observations on IPV and OPV vaccination. John TJ Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328 [TBL] [Abstract][Full Text] [Related]
16. Introduction of inactivated polio vaccine (IPV) into the routine immunization schedule of South Africa. Schoub BD Vaccine; 2012 Sep; 30 Suppl 3():C35-7. PubMed ID: 22939019 [TBL] [Abstract][Full Text] [Related]
17. Vaccine coverage and determinants of incomplete vaccination in children aged 12-23 months in Dschang, West Region, Cameroon: a cross-sectional survey during a polio outbreak. Russo G; Miglietta A; Pezzotti P; Biguioh RM; Bouting Mayaka G; Sobze MS; Stefanelli P; Vullo V; Rezza G BMC Public Health; 2015 Jul; 15():630. PubMed ID: 26156158 [TBL] [Abstract][Full Text] [Related]
18. Strengths and weaknesses of current polio vaccines--a view from industry. André FE Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338 [TBL] [Abstract][Full Text] [Related]
19. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Pliaka V; Kyriakopoulou Z; Markoulatos P Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246 [TBL] [Abstract][Full Text] [Related]
20. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Thompson KM; Duintjer Tebbens RJ Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]